BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Astellas Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Astellas Pharma's drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06792435-2360@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:ASP546C: Phase 1/2 readout est. (NCT06792435)
DESCRIPTION:ASP546C\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: XNW27
 011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.\
 nEstimated primary completion: 30 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/asp546c#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06792435
URL:https://assetmemo.bio/drug/asp546c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05970172-873@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Evrenzo (Roxadustat): Phase 3 readout est. (NCT05970172)
DESCRIPTION:Evrenzo (Roxadustat)\, phase 3\, Chronic Kidney Disease.\nStudy
 : A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chr
 onic Kidney Disease\nEstimated primary completion: 30 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/roxadustat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05970172
URL:https://assetmemo.bio/drug/roxadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052929-11064@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ASP2957: Phase 1/2 readout est. (NCT07052929)
DESCRIPTION:ASP2957\, phase 1/2\, X-Linked Myotubular Myopathy.\nStudy: Stu
 dy of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who N
 eed Ventilators\nEstimated primary completion: 31 October 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/asp2957#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07052929
URL:https://assetmemo.bio/drug/asp2957#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07475806-2121@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07475806)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: A Study 
 to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People Wi
 th Muscle-invasive Bladder Cancer Keep Their Bladder\nEstimated primary co
 mpletion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07475806
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421700-2121@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07421700)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2.\nStudy: Symbiotic-GU-06: A Stud
 y to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedot
 in in Urothelial Cancer\nEstimated primary completion: 28 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0742170
 0
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05520567-2038@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Gilteritinib: Phase 1/2 readout est. (NCT05520567)
DESCRIPTION:Gilteritinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A St
 udy of Gilteritinib\, Venetoclax and Azacitidine as a Combined Treatment f
 or People Newly Diagnosed With Acute Myeloid Leukemia\nEstimated primary c
 ompletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/gilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05520567
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287995-2121@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07287995)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2.\nStudy: A Study of ASP2998 Give
 n by Itself and Given With Standard Therapies in People With Solid Tumors\
 nEstimated primary completion: 30 June 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07287995
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07488676-2360@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:ASP546C: Phase 1/2 readout est. (NCT07488676)
DESCRIPTION:ASP546C\, phase 1/2.\nStudy: A Study of ASP546C in Adults With 
 Gastroesophageal Cancer\, Pancreatic Cancer or Other Solid Tumors\nEstimat
 ed primary completion: 31 July 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/asp546c#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07488676
URL:https://assetmemo.bio/drug/asp546c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07409272-2183@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Setidegrasib: Phase 3 readout est. (NCT07409272)
DESCRIPTION:Setidegrasib\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nStu
 dy: A Study to Evaluate the Effectiveness and Safety of Setidegrasib\, Giv
 en With Either mFOLFIRINOX or NALIRIFOX Chemotherapies\, in People With Pa
 ncreatic Cancer\nEstimated primary completion: 31 August 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/setidegrasib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07409272
URL:https://assetmemo.bio/drug/setidegrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566156-2121@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Enfortumab Vedotin: Phase 3 readout est. (NCT07566156)
DESCRIPTION:Enfortumab Vedotin\, phase 3\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiother
 apy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)\nEstimat
 ed primary completion: 31 March 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07566156
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566052-2183@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Setidegrasib: Phase 3 readout est. (NCT07566052)
DESCRIPTION:Setidegrasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Compare Setidegrasib (ASP3082) With Docetaxel\, in People With No
 n-small Cell Lung Cancer With a KRAS G12D Mutation\nEstimated primary comp
 letion: 30 June 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /setidegrasib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07566052
URL:https://assetmemo.bio/drug/setidegrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722988-873@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Evrenzo (Roxadustat): Phase 3 readout est. (NCT07722988)
DESCRIPTION:Evrenzo (Roxadustat)\, phase 3\, Myelodysplastic Syndromes.\nSt
 udy: A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592
 ) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
 \nEstimated primary completion: September 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/roxadustat#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07722988
URL:https://assetmemo.bio/drug/roxadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673887-11060@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:ASP2138: Phase 3 readout est. (NCT07673887)
DESCRIPTION:ASP2138\, phase 3\, Gastric Cancer.\nStudy: A Study of ASP2138 
 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
 \nEstimated primary completion: 28 February 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/asp2138#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07673887
URL:https://assetmemo.bio/drug/asp2138#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005154-11062@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Abiraterone decanoate: Phase 2 readout est. (NCT07005154)
DESCRIPTION:Abiraterone decanoate\, phase 2\, Prostate Cancer.\nStudy: A Ph
 ase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prosta
 te Cancer\nEstimated primary completion: 31 May 2032. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/abiraterone-decanoate#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07005154
URL:https://assetmemo.bio/drug/abiraterone-decanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876804-11064@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20320731
DTEND;VALUE=DATE:20320801
SUMMARY:ASP2957: Phase 1/2 readout est. (NCT07876804)
DESCRIPTION:ASP2957\, phase 1/2\, X-Linked Myotubular Myopathy.\nStudy: A L
 ong-term Follow-up Study in Male Participants With X-linked Myotubular Myo
 pathy Treated With ASP2957\nEstimated primary completion: 31 July 2032. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/asp2957#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07876804
URL:https://assetmemo.bio/drug/asp2957#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04174105-11065@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20350228
DTEND;VALUE=DATE:20350301
SUMMARY:Zocaglusagene nuzaparvovec: Phase 1/2 readout est. (NCT04174105)
DESCRIPTION:Zocaglusagene nuzaparvovec\, phase 1/2\, Pompe Disease.\nStudy:
  Gene Transfer Study in Patients With Late Onset Pompe Disease\nEstimated 
 primary completion: 28 February 2035. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zocaglusagene-nuzaparvovec#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04174105
URL:https://assetmemo.bio/drug/zocaglusagene-nuzaparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
